Good afternoon, and thank you for joining us today to discuss OptimizeRx Third Quarter ended September 30, 2018. With us today is the Chief Executive Officer of OptimizeRx, William Febbo; he is joined by the company’s President, Miriam Paramore; and its Chief Financial Officer, Doug Baker. Following their remarks, we'll open your call to questions. Then before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made by management during today's call. I'd also like to remind everyone that today's call is being recorded and will be made available for telephone replay via instructions in today's press release in the investor's section of the company's website. Now, I'd like to turn the call over to OptimizeRx, CEO, Will Febbo. Please go ahead.

Thank you, Greg, and good afternoon, everyone. Thanks for joining us on the call today. As you all saw from today's earnings release, we made a lot of progress in growing our digital health messaging platform. On the call today, we'll look to talk about our record quarter and the foundation we've been laying to support future growth and expansion. We continue to achieve growth and improvement across the board in Q3, in fact we realized our eighth consecutive quarter of revenue growth and our second consecutive quarter of profitability. Revenue was up 75% from the year-ago quarter and up 6% sequentially to a record $5.4 million. These results reflect strong client demand and expanding budgets, which we believe is due to the high return on investment on marketing dollars we offer to our clients. We also see accelerating opportunities and progress with market adoption of our platform, the need for more assistance with co-pays on branded medications and continued growth around additional access to physicians in both ambulatory and hospital settings. Our expanding reach to physicians at point of care together also continues to fuel our growth. So far this year, we've launched with seven new EHRs, and we've exceeded most of our internal revenue goals. Even with this strong progress, we believe we've only just begun to open the market and feel adoption will only increase. At the risk of referring to baseball and being from the Boston area, we feel we're in the third inning from my perspective, so still very early. Of the 2 billion e-prescriptions transmitted annually nationwide, still only 10% involve brands with copay savings programs. This means OptimizeRx has the potential to deliver more than 200 million transactions annually at the current level. Naturally, we expect to see e-prescription market grow over time…

Thanks Will, and good afternoon, everyone. Prior to the call, we issued a press release with the results of our third quarter ended September 30, 2018. A copy of that release is available on the Investor Relations section of our website. We reported that net revenue in the third quarter of 2018 increased 75% to a record $5.4 million. The increase is primarily due to growth in our two core digital messaging products, financial and brand messaging coupled with broader distribution through our new channel partners. The launch of new pharmaceutical brands also contributed to the increase. Strong revenue growth in the third quarter increased our gross margins to 58.1% as compared to 45.1% in Q3 of last year. This big improvement was due primarily to product mix and our focus on reduction of our revenue share expense. We remain focused on maintaining these improved profit margins in 2018 and we expect to achieve our gross margin target of at least 55% through the fourth quarter of 2018. Our operating expenses in the third quarter of 2018 were $2.9 million, up from $2 million in the same year ago quarter. This increase is primarily due to additional expenses related to our growth initiatives. It's important to note however that our operating expense as a percentage of revenue decreased to 54%. This is a big improvement from the 65% of revenue in the same year ago quarter. We expect our operating expenses to naturally increase over time, as we pursue our growth plans and expand our operations to support a growing customer base and partner network. However, for the foreseeable future, we expect to see operating expense as a percentage of revenue continuing to decline, supporting improvement in profitability. This was evident in our strong third quarter where we achieved our…

Thanks, Doug. We have been executing on our growth plan, and I'm happy to share a little more detail about our achievements this quarter. First, I'd like to discuss our platform development and provide an update on our product roadmap. I'll give a brief update on our operational improvements and finally I will talk about our broadening reach to healthcare providers or HCPs, through the expansion of our point of care network including our hospital strategy. We have continued to invest in the underlying technology that powers our solutions, including our broader data strategy. We hired a new technical data leader and increased the size of our software development team. Our new data warehouse represents the underpinning of a new reporting and data analytics capability that is designed to provide value insights to our customers. These efforts are expected to support future growth and additional recurring revenue, as well as significantly strengthen our value proposition. Future investments in such growth initiatives may result in some quarterly fluctuations in profitability as Doug mentioned, but our shareholders can expect these investments to drive further strong top-line growth, margin expansion and to sustaining our position as the clear market leader. Regarding our product roadmap, we remain focused on organically building launching and growing our suite of products and services. One initiative is to facilitate faster ramp up and higher utilization by our EHR and e-prescribing partners that are still running on legacy server-based technologies. These partners have complex software upgrade cycles that must be carefully managed and we hope to make the process as easy as possible when it comes to working with our technology. To that end, in Q3, we launched our channel partner portal which allows our EHR and e-prescribing partners to quickly and easily review and approve pharma programs. The…

Thanks, Miriam, and thanks, Doug proud of you guys and proud of the whole team, nice work. Over the last few years we emerged as the only public company that’s been able to effectively address the challenge of escalating drug cost, patient adherence and pharma doctor communication and do it with a simple solution delivered right within a doctor’s everyday workflow. As the largest digital health network of its kind, OptimizeRx provides patient access to savings directly through the doctor managed EHR and e-prescribing system. This point of care presence has become increasingly essentially given how EHRs today dominate the attention of HCPs known as doctors. Most physicians now spend more than five hours a day interacting with patient health records through the EHR interface, whether it’d be doing test results or logging notes or issuing e-prescriptions. As I mentioned earlier in 2017 alone more than 2 billion e-prescriptions were transmitted from doctor to pharmacy. This phenomenally high number reflects how 90% of the ambulatory care providers now use EHRs and that e-prescribing now exceeds 85% of all prescriptions written according to a 2018 SureScripts report, in fact most hospital systems now require that all medication be e-prescribed. Our powerful digital healthcare messaging platform provides critical communication between pharma companies and healthcare providers, where providers can be alerted to available financial programs right at the point of care, in real time the patient savings solution check eligibility and delivers an offer to the prescribing physician. The voucher or coupon is then printed for the patient to present to their pharmacist or sent along with the prescription electronically. By delivering patient savings in clinical content from pharmaceutical manufacturers directly through the EHR at the point of care, doctors are alerted to opportunities during the e-prescribing processes and natural part of their…

[Operator Instructions] And first we have Andrew D'Silva with B. Riley FBR.

Don't know if you mentioned this, but can you give a little color on the trajectory of the company, particularly with Medicom? How is that integration going in your opinion at this point? How could it work to get you more broadly accepted into Cerner and Epic’s platforms, any color on that would be really valuable.

Yes, Andy hey. Good to hear your voice. We talked a little bit about it last call. The hospital systems, obviously completely a new area for us. Epic and Cerner dominate there. This partnership gets us into 600 hospital systems over the course of next year. Those will roll out in chunks if not all at once it's not immediate and we don't break out revenue by channel, but that's a significant increase in access to physicians. It's also a very valuable access point for our clients. So we expect that to be part of our growth next year. I would say as an integration partner, they're doing really well. They’ve been around for a while and they are already integrated with their core offering. So, this not a start-up that's trying to figure it out, this is an established company with a great team.

Okay. Could you maybe provide a little bit of a breakout if you were to look at the market, and you provided that $1 billion TAM number, which was very useful, but maybe break out between the ambulatory and the traditional hospital market will may be put things into context of how large the opportunity is with Medicom and then just integrating further into the hospital channel?

Yes, I mean, I would say $1 billion doesn't include the hospital systems at all, because traditionally it just couldn't get to them. If you think of what we're defining in that $1 billion, it's really a marketing spend from pharma in point of care. That's more than just the EHR channel that's other companies, websites like WebMD, Medscape, and others. So I view this as all incremental growth and greenfield growth, and that's why we don't want to get too far ahead of ourselves and say it's going to double our business; it's not that, it's not that big of a reach, it's a good group of hospital systems, and then we're selectively prioritizing other hospital systems next year that we know our clients are interested in that aren’t in that 600. But this just increases the market, and I did talk about increasing opportunities. This would be part of that description because this is a new set of physicians that we can get a message to, and given all the specialty drugs coming out and the amount of information needed and how expensive copays are, we think we're getting in there at the right time.

Got it. Okay, great. And then moving over to the CareSpeak acquisition. You provided a lot of color on the call about that, but maybe you could just discuss some of the nuances of the platform as it relates to its scalability? Is it similar in the way your legacy platforms built, where everything can essentially build on top of that and flow down to the free cash flow fairly easily, or is it take a little bit more investment as you scale up in the traditional business?

The quick answer is, early days it will take some investment, but then it can have nice scale afterwards. And the way it scales is by getting domain expertise in a given therapeutic disease state. And they've done some good work in two or three and we're going to focus on really leveraging those first. And it needs some additional investment, but we think that the timing is really perfect on this and we love the connectivity to the copay. Because to-date, if you think of the two, adherence and affordability, they just go together. And the pharmaceutical companies have been focused on it for years with paper and using reps to handout information or tear sheets at pharmacies. I mean, they've tried everything because it's such as a big issue. We think overtime, we can bring these two together and the value proposition is so strong, and we can track it as Miriam said, which is becoming very important, and it's not just immediate spend, this is a real hardcore marketing spend that can affect both of those. But what's most exciting to me, I think is we've got this sales team now that can take this offering across the hall to another decision maker within a brand from a different budget that we couldn't talk to three weeks ago, right so now we've got an expanded client base and some great growth opportunity there.

And so that those synergies are fairly significant. The overlap that your sales team will be able to have cross-selling that product, you envision that being almost one to one as far as every salesperson you have will be able to go into almost all their clients and try at least attempt to cross sell at CareSpeak?

No question.

Okay, fantastic. And just last one you might have touched on this new channel partners year-to-date, did you give an update on that?

Yes, we just gave the macro number of seven for the year Mediacom being the biggest one of late.

Okay, great, perfect. Thank you so much and good luck going forward.

Thanks, Andy.

Moving on we have Richard Baldry with ROTH Capital.

Thanks. Your seasonality tend to be pretty strong in the second and fourth quarter. So we're partway through the fourth quarter now. So I was curious with CareSpeak even adding on top of that for a revenue scale. How you're feeling about that similar seasonality and whether you think that also trends the same sort of into 2019?

Hey, Rich. Yes. No, I don't see any interruptions to the seasonality that we've seen in past years. Feeling very good about the business. We've had good pickup with client's additional reach to HCPs. Yes, there'll be some small incremental add for Q4 for CareSpeak, although most of it will be you know pure organic growth. And going into 2019 we've deepened RFPCs and we're feeling really good about it. We would end with I think a bigger team than we've ever had more solutions and since it’s still RFPCs and we're also now integrating CareSpeak into some of these assets for next year. So timing is really good.

Then maybe look at the COGS line. Your revenues grew pretty solidly sequentially the COGS was essentially flat. So you maybe keep into the drivers there and how that can be flat even when revenues are growing. So we get a better sort of feel for the long-term trending. Thanks.

Sure, Rich. Yes, it's a mixture of a lot of things. We've got lots of contracts that involve different sorts of percentages and payouts and it's also a product mix. So this quarter really showed because we had a good product mix basically. So we drop a couple of more percentage points down. I think as an investor or as an analyst doing the model the 55% is a good bogey. We may beat it on occasion and we may be slightly above it on occasion, but that's what we're holding ourselves to internally and we're starting to see a nice drop to the bottom.

Last thing on the -- as you scaling up pretty fast you’ve been bringing on more executives broaden the team. How do you feel about that now and what do you expect from the executives brought over in the CareSpeak side of the table? Any hold [ph] or positions you feel like you look forward to adding now that the scale sort of coming up? Thanks.

No, I feel really good about the team. I think we've got at a corporate level a very solid team to handle growth and building I know on the sales side, Terry Hamilton, has just done a stellar job and continues to attract great people and building a really good team culture. The CareSpeak team is self-sufficient. They are the two executives there that are based in New Jersey are pharma professionals and very bright and they'll be great on the team and they'll head up our patient engagement group. And then, we have a great technology team over in Croatia now that access our tech team, but they are fully on the team they're not outsourced. So I don't have any immediate big plans. I think we've got our senior executive team and it's really about filling in the team around execution.

Great, congrats on a great quarter.

Thanks, Rich.

Thank you.

Moving on we have Eric Martinuzzi with Lake Street.

Congrats on the quarter. It's terrific that 75% growth number, but also keeping a lid on expenses too to turn that into cash flow. So congrats. Question on the Q4 revenue outlook, I know you guys aren't in the guidance business, but you did pick up a small amount of revenue from CareSpeak. We also have your normal seasonal trends. I think you talked about a stair step throughout the year. So just -- maybe just starting with where the consensus is for Q4, that $5.8 million that's in the consensus would -- are you guys comfortable with that, is that a number that you guys feel you can achieve?

That was kind of be giving guidance with another factor. No…

No, really…

I'm just teasing, Eric. No the business is doing well. We don’t have any big brands that are going off patent, and we’ve got some visibility now, which is really six months visibility. So I feel good about Q4 and a little bit addition from CareSpeak helps that out. So, yes, I'm feeling good about the quarter.

Okay. And then just looking out in 2019, historically there has been a step back on the gross margin side sometimes it’s on boarding a new distribution partner lot of times theirs is that investment in getting the pluming right and we see a fall-off in gross margin with the start of a new year, should we anticipate that as well in 2019?

Yes, I think I brought it up a little bit, I’d bake in a 2% to 3% swing through -- maybe through the year based on whatever we end up at the end of Q4. I think it’s safe there are some integration partners that we have those take time, we’re working on hospital system strategy that’s going to -- that’s a new area for us. So sometimes in new areas you need to pay a little bit upfront as we know. And then I think getting the CareSpeak to really work well I think overtime that’s where we’ll make it all back.

Okay. Next question is for Miriam, you’ve talked a little bit about the platform, the product roadmap, interested to hear about the new data warehouse. Where is that, is that pointed internally or is this optimize use, is this something that’s going to be productize, something for your pharma customers, is it distribution channel partners tell me a little bit more about the data warehouse?

Sure, I'm happy to. It really is all three, so there is a lot of benefits for Optimize on internal operations based on visits intelligence reporting. So we have all with these hundreds and hundreds of thousands of transactions running through our system daily. And we learn a lot from that and we’ve many, many, many channels and hundreds of programs running at any point, so multiple endpoints. So seeing where the traffic is going and where it’s not going and why and is kind of what I was referring to when I said tuning. So we have found enormous benefit from having that inside into our operational efficiency and utilization we can tune to a more throughput benefit for all parties. So that’s a good use of it from a business intelligence point of view. With respect to our pharma customers, we are using our data warehouse with our new Data Analytics Head, Carlo Luchi [ph] and try to say that three times fast that’s a mouthful but he’s fantastic. We’re working just really daily with our current customers who ask a variety of questions about value and return on investment and insights that we can get into the ROI of programs that are currently running or -- and or the ROI of programs that we’re looking at running. So based on the data exchange that we have with our various partners, Eric, we can calculate ROI in a variety ways. So getting those analytics in front of our customers interactively as they ask for them and then retrospectively as programs launched and run is very, very valuable to ongoing business and to keeping programs active because they can see the ROI very, very clearly. So…

Okay. But this isn’t something that will be productize it’s just -- it’s something that it helps them it’s part of their -- part of the purchase price kind for them on a…

Well there’s one aspect of it that we maybe productizing and I’ll say that we may be productizing is the right way to put it. So there as we tune for as we share data insights based on our early day analytics, we’re learning more about what data provides insights that have value. And so we’re looking at some things that may have ongoing value and that’s to compel their own revenue line. But today, we're already experiencing increased and more continuous ongoing revenue as a result of doing this. So that's our goal Eric, is to figure out if we can kind of narrow in on that, and productize it. But the last piece I will tell is EHR facing and you asked if we were using it for our EHR partners and we are, and that was that channel partner portal that I mentioned, because we have now interactive workflow tools with notifications and kind of seamless, self-service type of tools that work with us and work with our channel partners to get programs turned on faster. We're using that same data warehouse to power analytics reports that the channel partners can look at to say how programs are performing, from their point of view. Because, they're part of the supply chain too. So it really has three purposes. And we -- our aim is productization, but it's just early for me to say that what we get to and when we get there on productization.

Understand. The last question for me is for, Doug, these are a couple of housekeeping items, Doug, with regard to the CareSpeak acquisition, which happened -- which closed after the turn of a quarter. Just wondering the cash balance you reported $13.5 million at quarter end, I think you said you use $6 million on the acquisition. So is $7.5 million a good pro forma cash number? And then also, what share account should we be using for Q4?

So, yes, that's $7.5 million is a good cash number and then share count, there's only about 30,000 shares issued with CareSpeak. So the number on this front of the 10-Q was like $12 million and 13,000 shares. So that'd be pretty good for Q4.

Got you. Okay, thanks for taking my question.

Thanks, Eric.

[Operator Instructions] Moving on we have Harvey Poppel with PopTech.

Yes. So Will, congratulations on once again another great quarter; knocking it out of the ballpark here, certainly this year and the last several quarters of the prior year. Though you've already developed and are developing a number of new adjacent market and product opportunities that are going to be quite large. And at the risk of sounding greedy, there are some other parallel universes out there, I wonder if you could speak to. One is international and the other is generics.

Sure. Thanks, Harvey. And it's yes, as the whole team as you know, takes a team you run a business. So on international, we do have a partnership with a company called Patient Connect based in the UK. The idea there is that they have the largest pharmacy based network and they are integrated into some of the EHRs. We've been so busy with organic growth that we haven't dedicated a lot of time to that partnership. But the rationale is that we work with global brands and global brands will want to do messages in Europe as well. And then it's obviously not around the copay, it's more around clinical and adherence messaging. So we'll continue to look at that and update people as we look at other markets as well, including South America and Asia. Although, I will say the domestic market is so big that we won't let it distract us from capturing more market share here. And -- but I'm encouraged by it and I think it has a lot of opportunity. And I do think -- sorry, what was your second one, Harvey?

Generic.

Generics. Yes, sorry. So we have a partnership right now with a company called SingleCare. They are similar to GoodRx or Blink, which is to give cash discounts on generics. We have them currently integrated into several of our channel partners, and we're working to get them into several more. And I think it's up to over 900 programs that we have in there. And very similar idea, similar workflow. We all know that generic is 80% of -- almost 90% of the prescription activity. So it's an important space to be in. The model is a little different though, in that we only get paid if a patient uses that discount versus the branded, which is really if it’s just distributed or connected to a prescription. So we're in that space and excited about it making some additional technology investments to make sure we can get more savings to more patients on all drugs.

Good, thanks a lot.

Thanks, Harvey. Have a good night.

Our next question comes from Ron Chad [ph].

Good afternoon. And it's nice to hear Will, you giving credit to everybody else. That's a good thing your pride in their performance. So good for you. And are you continuing to have an active effort with regard to acquisitions you bolt-on acquisitions or are you just taking it easy for a bit?

Well it's never good that the CEO is taking it easy for a bit. So I'll say I'm not taking it easy. We did do a pretty comprehensive process through the summer looking at targets, some of which were maybe a little too big for us. And so we felt this one was the right size, the right fit and really nice connection to our core solution set. But there are others out there that I like. And so we'll continue to look at those. We're not a big organization so we can't do too much too fast on that front, but we will continue to look to answer your question.

Yes, a question for Doug, which is pertaining to it a little bit now, you'll be able to use NOLs going forward?

Yes.

Okay. And one second please. You talked about further recurring revenue, you want to comment a little further on that please?

Well, I think the reference it was probably made within data and analytics. The challenge we've given ourselves is to figure out how to work with our clients to be able to give them insights and data around the activity around prescribing and messaging and effectiveness. And those models generally are more SaaS in nature than our current offering. So we're working on that we now have the team that can execute against it. So we're -- we'll have more to report later on that. But I will say that most of our core business on brands that are far from going off patent. It really is repairing in the sense of we measure it, it shows good return and clients come back and they give us 12 month engagements. And we're deep into that RFP process and seeing some nice upticks across the board with our clients in the past we've said we've had a few $1 million clients. I think that was two years ago. Last year we said we had one $2 million and a bunch of $1 million. Now we've got several over $3 million and we're building from there. So I feel like we're really building a nice client base.

So one more question. Do you get calls? I ask about your bolt-on efforts with regard to M&A, do you get calls from other people interested in acquiring Optimize?

The calls that have come in had been more on the private equity side that maybe firms that aren't in the space yet. But want to be a lot of sniffing, a lot of dancing. But we don't let those distract those. we just keep doing what we're doing and if the right suit calls that will be obvious.

Good job. Keep up the hard work, okay.

Thanks Ron. Appreciate the support.

Alright. And at this time, that concludes our question-and-answer session. I'd now like to turn the call back over to Mr. Febbo. Please go ahead, sir.

Thanks, Greg and thanks everyone for joining the call. I really believe in our potential as a company to deliver this continued revenue growth, margin improvement and our profile in the industry has just gotten stronger and stronger. I was really happy to be part of a conference where I saw Miriam giving a panel discussion with Dr. Jay Penny [ph] who's on our medical advisory board. And I love the fact that we were there amongst very large companies with a real presence. It was the way we announced the acquisition, lot of buzz. And we were one of the few vendors in a Health Tech Conference that decided to bring a doctor to talk about what's useful. And I think that's how I think we've got a culture of trying to do something makes a difference that has impact. And when you can do that and grow and be profitable on cash flow, and be early in that process. I think we're on do some really exciting stuff here. So I am really fired up and I appreciate everyone’s time today. Thank you.

Thank you ladies and gentlemen, and now before we conclude today's call, I'd like to provide the company's Safe Harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today’s call may contain forward-looking statements within the definition of Section 27A in the Securities Act of 1933 as amended, and the Section 21E of the Securities Act of 1934 as amended. These forward-looking statements should not be used to make investment decisions. The words anticipate, estimate, expect, possible and seeking and similar expressions identify forward-looking statements and they speak only to the date the statement was made. Examples of such forward-looking statements in this presentation include statements regarding continued strong top line growth, gross margin targets; expectation to see operating expense as a percentage of revenue continuing to decline, with the supporting improvement in profitability, expectation to continue to be profitable on a quarterly basis, although one-time expenses related to investments and growth initiative could result in the quarterly loss in any particular quarter, expectation to end 2018 with positive cash flow from operations for the year, estimation of total addressable market size. For the foreseeable future, the company doesn’t seem to need to raise any additional capital solely for operating purposes, the broader data strategies supporting future growth and additional recurring revenue and significantly strengthening the company‘s value preposition, investments driving further strong top line growth, margin expansion and sustaining its position as the clear market leader, pilot for clinical messaging solution in Q4, plan to make additional sales and channel investments for expanding further into its core ambulatory market, launching with three hospitals by early January 2019, revenue from its new international efforts to ramp up in 2019. CareSpeak helping to optimize our capture more client budget for brand, increased adoption of the company’s digital health platform in cloud based EHR channels, hospital systems and ultimately by potential clients. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in/or contemplated by underlying forward-looking statements, risks, and uncertainties to which forward-looking statements are subject to could affect business and financial results are included in the company's annual report on form 10-K for the fiscal year ended December 31, 2017. The form is available on the company's website and on the SEC website at sec.gov. Before we end today's conference, I would like to remind everyone that this call will be available for replay starting later this evening and running through November 26th. Please refer to today's press release for dial in replay instructions available via the company's website at www.OptimizeRx.com. Thank you for joining us today. This concludes today’s conference call. You may now disconnect.